Managing Endocarditis Workup

Documents to Request

• Blood culture results with organism identification and sensitivities
• TTE and/or TEE reports
• Cardiac CT or PET/CT if performed
• CT head, chest, abdomen/pelvis (embolic workup)
• MRI brain (if neurologic symptoms)
• Dental examination report
• Current and recent antibiotic regimen
• Recent procedures or hospitalizations (source investigation)
• Labs: CBC with differential, CRP, ESR, procalcitonin, BMP, LFTs, urinalysis
• Rheumatoid factor, complement levels (if immune complex disease suspected)

Step 1: Blood Culture Protocol

Proper Blood Culture Technique (Critical for Diagnosis):

• Draw ≥ 3 sets (aerobic + anaerobic) from separate venipuncture sites
• Each set should contain 20 mL of blood (10 mL per bottle)
• Draw before initiating antibiotics whenever possible
• Spacing: at least 1 hour apart if subacute presentation; can draw within 1 hour from separate sites if acutely ill
• Do not draw from indwelling lines unless concurrent peripheral cultures are obtained (to distinguish bacteremia from line colonization)

Culture-Negative Endocarditis (5–10% of cases):

• Most common cause: prior antibiotic exposure
• Special organisms requiring extended incubation or serology:
  • HACEK organisms: hold cultures for 2 weeks (most modern systems detect within 5 days)
  • Coxiella burnetii (Q fever): phase I IgG ≥ 1:800 (major Duke criterion)
  • Bartonella: serology (IgG ≥ 1:800) or PCR
  • Brucella: serology
  • Tropheryma whipplei: PCR on blood or tissue
  • Fungi (Candida, Aspergillus): blood cultures, beta-D-glucan, galactomannan
• If negative at 5 days: notify lab for extended hold; send serologies for atypical organisms

Step 2: Modified Duke Criteria Application

Major Criteria:

1. Positive blood cultures:
   • Typical IE organism (Viridans streptococci, S. bovis, HACEK, S. aureus, Enterococcus) from ≥ 2 separate cultures
   • OR persistently positive cultures: ≥ 2 cultures drawn > 12 hours apart; OR all of 3, or majority of ≥ 4 separate cultures with first and last drawn > 1 hour apart
   • OR single positive culture or serology for Coxiella burnetii (phase I IgG ≥ 1:800)
2. Imaging evidence of endocardial involvement:
   • Echocardiographic: vegetation, abscess, pseudoaneurysm, intracardiac fistula, valvular perforation, new partial dehiscence of prosthetic valve
   • OR new valvular regurgitation (worsening of pre-existing is insufficient)
   • OR abnormal activity on PET/CT around prosthetic valve (> 3 months post-implant)
   • OR paravalvular lesions on cardiac CT

Minor Criteria:

1. Predisposing heart condition or IV drug use
2. Fever ≥ 38.0°C (100.4°F)
3. Vascular phenomena: major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages, Janeway lesions
4. Immunologic phenomena: glomerulonephritis, Osler nodes, Roth spots, positive rheumatoid factor
5. Positive blood cultures not meeting major criterion

Diagnostic Classification:

Step 3: Echocardiographic and Advanced Imaging

TTE vs. TEE Decision:

TTE Sensitivity: ~50–60% for native valve IE; ~30% for prosthetic valve IE TEE Sensitivity: ~90–95% for native valve IE; ~85–90% for prosthetic valve IE

Advanced Imaging (2023 Guidelines):

• 18F-FDG PET/CT: Recommended for prosthetic valve IE and device infections; detects perivalvular abscess and embolic foci. Suppress physiologic myocardial uptake with 24-hour high-fat, low-carb diet.
• Cardiac CT: Identifies abscess, pseudoaneurysm, fistula with high spatial resolution; useful when TEE is equivocal.
• Whole-body CT (head, chest, abdomen/pelvis): Embolic complication screening — splenic infarcts/abscess, renal infarcts, vertebral osteomyelitis, pulmonary septic emboli.
• MRI brain: Most sensitive for cerebral emboli (50% of IE patients have silent CNS emboli).

Step 4: Complication Assessment

Embolic Complications (occur in 20–50% of IE):

• CNS: ischemic stroke, hemorrhagic transformation, mycotic aneurysm, brain abscess
• Splenic: infarction, abscess
• Renal: infarction, immune complex GN
• Pulmonary: septic emboli (especially right-sided IE from IV drug use)
• Peripheral: Janeway lesions (painless erythematous), Osler nodes (painful, immune-mediated)

Perivalvular Complications:

• Abscess: identified on TEE or CT; significantly increases surgical urgency
• Fistula: intracardiac communication (e.g., aorto-cavitary)
• Pseudoaneurysm: contained rupture
• Heart block: new conduction abnormality suggests septal abscess extending to conduction system

Indications for Early Surgery (during initial hospitalization):

1. Heart failure from valve dysfunction (Class I)
2. Uncontrolled infection: persistent bacteremia > 5–7 days on appropriate antibiotics, perivalvular abscess, infection by resistant organisms (fungi, MDR)
3. Prevention of embolism: recurrent embolic events despite appropriate antibiotics; large mobile vegetation (> 10 mm) especially on mitral valve with prior embolic event
4. Prosthetic valve endocarditis with any of the above
5. Fungal endocarditis (almost always requires surgery)

Step 5: Antibiotic Management Framework

Empiric Therapy (before cultures return):

• Native valve: vancomycin + ceftriaxone (covers Staph, Strep, Enterococcus, HACEK)
• Prosthetic valve: vancomycin + gentamicin + rifampin (covers Staph including CoNS)
• IV drug use / right-sided: vancomycin (primarily S. aureus)

Duration of Therapy:

Clock starts from first negative blood culture, not from initiation of antibiotics.

Checkpoint B: Post-Draft Alignment (Mandatory)

1. Are blood culture technique details documented (sets, timing, pre-antibiotic status)?
2. Is the modified Duke classification applied with each criterion documented?
3. Was appropriate imaging performed (TTE vs. TEE decision justified)?
4. Is the embolic complication assessment complete?
5. Are surgical indications explicitly evaluated?

Quality Audit

• ≥ 3 blood culture sets drawn before antibiotics (or timing documented)
• Modified Duke criteria applied with each criterion explicitly scored
• Diagnostic classification stated: definite, possible, or rejected
• TTE performed; TEE performed when indicated (prosthetic, device, S. aureus, negative TTE)
• Vegetation size and location documented
• Perivalvular complications assessed (abscess, fistula, perforation)
• Embolic workup completed (brain MRI, CT abdomen, splenic imaging)
• Portal of entry investigated and documented
• Surgical indications systematically evaluated
• Antibiotic regimen appropriate for organism and valve type
• Treatment duration and clock start documented
• Culture-negative workup pursued if applicable (serologies, PCR)
• Dental evaluation obtained
• Follow-up blood cultures documented to confirm clearance

Guidelines

1. Never draw blood cultures from indwelling lines alone — always obtain at least two sets from peripheral venipuncture sites for diagnostic reliability.
2. TEE is required for all prosthetic valve endocarditis, intracardiac device infections, and S. aureus bacteremia — TTE sensitivity is insufficient in these populations.
3. A negative TTE does NOT rule out endocarditis when clinical suspicion is high — repeat TTE in 5–7 days or proceed to TEE.
4. PET/CT is most useful for prosthetic valve and device infections where echocardiography is equivocal — it should not be performed within 3 months of cardiac surgery (false positives from surgical inflammation).
5. Duration of antibiotic therapy starts from the first day of negative blood cultures — not from the day antibiotics were initiated.
6. Indications for surgery should be evaluated by a multidisciplinary endocarditis team (cardiologist, cardiac surgeon, infectious disease) at the time of diagnosis — do not wait for treatment failure.
7. In right-sided endocarditis (IV drug use), surgical threshold is higher than left-sided — many cases can be managed medically unless vegetations are very large or persistent bacteremia despite appropriate therapy.
8. All patients with endocarditis should be screened for CNS complications with brain MRI — cerebral emboli are found in up to 50% and may alter surgical timing.